Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders

Monge-Fuentes, VictoriaGomes, Flávia Maria MedeirosCampos, Gabriel Avohay AlvesSilva, Juliana de CastroBiolchi, Andréia MayerAnjos, Lilian Carneiro dosGonçalves, Jacqueline CoimbraLopes, Kamila SoaresMortari, Márcia Renata

The impact of neurological disorders in society is growing with alarming estimations for an incidence increase in the next decades. These disorders are generally chronic and can affect individuals early during productive life, imposing real limitations on the performance of their social roles. Patients can have their independence, autonomy, freedom, self-image, and self-confidence affected. In spite of their availability, drugs for the treatment of these disorders are commonly associated with side effects, which can vary in frequency and severity. Currently, no effective cure is known. Nowadays, the biopharmaceutical research community widely recognizes arthropod venoms as a rich source of bioactive compounds, providing a plethora of possibilities for the discovery of new neuroactive compounds, opening up novel and attractive opportunities in this field. Several identified molecules with a neuropharmacological profile can act in the central nervous system on different neuronal targets, rendering them useful tools for the study of neurological disorders. In this context, this review aims to describe the current main compounds extracted from arthropod venoms for the treatment of five major existing neurological disorders: stroke, Alzheimers disease, epilepsy, Parkinsons disease, and pathological anxiety.(AU)